When the sponsor-investigator holds the IND for an investigational drug, he or she is responsible for annual reporting of a brief progress report on the state of the investigation to FDA, formally the annual report required by 21 CFR 312.33. That single report covers enrollment status, adverse events, protocol deviations, and a year-ahead plan, and it is due within 60 days of each anniversary of the IND's effective date.
The question trips up clinicians because "annual reporting" sounds like a single form. It is actually a fixed content package tied to a date, and the same person who treats patients must also compile it. Below, the mechanics, the numbers, and the failure modes.
What the regulation actually demands
The annual report exists because FDA needs a periodic, structured snapshot of every active IND, whether it is run by a large company or a single academic physician. Under 21 CFR 312.33, the report has defined content: a brief progress summary, enrollment data broken down by age, race, and sex, a narrative or tabular summary of the past year's adverse events, a description of any protocol changes, a summary of nonclinical and clinical information not previously submitted, and a plan for the coming year. The regulation also requires a brief description of the general investigational plan.
The purpose is not to re-license the trial. It is a longitudinal checkpoint. FDA reviewers use the annual report to see whether the investigation is advancing, whether safety signals are accumulating, and whether the sponsor's own assessment of risk has shifted. The report is due within 60 days of the anniversary of the date the IND went into effect (21 CFR 312.33(a)). That anniversary date, not the date the first patient enrolled, anchors the entire schedule.
One plain-language way to hold it: the annual report is the IND's birthday card to FDA, and it must arrive within 60 days of the birthday.
Why the sponsor-investigator bears the duty
In commercial drug development, the sponsor (a company) and the investigator (a site physician) are different legal entities. The company holds the IND and files the annual report. The sponsor-investigator model collapses those roles into one person: the physician initiates the investigation, holds the IND, and treats the patients. FDA built the sponsor-investigator designation precisely for this case, and the accompanying responsibilities are defined in 21 CFR 312.3(b).
The mechanism matters. The annual report is not a courtesy to the reviewing division. It is a regulatory obligation whose breach can trigger a clinical hold under 21 CFR 312.42, because an unreported or incomplete annual report signals that the sponsor may not be maintaining the IND in compliance. That is the counterintuitive detail many thin explainers omit: missing the annual report is not a paperwork slap. It is a potential trial-stopping event.
A second layer is the investigator's separate duty. Even where a commercial sponsor holds the IND, the investigator must report serious adverse events to the sponsor, and the sponsor then reports to FDA. In the sponsor-investigator model, that two-step relay disappears. The same person receives the safety signal and files it. The annual report is where the year's safety picture is consolidated.
Timeline: the annual reporting cycle
The dates below describe the statutory schedule under 21 CFR 312.33(a) and related IND requirements. They are general regulatory mechanics, not advice for a specific protocol.
| Stage | Timing | What happens |
|---|---|---|
| IND effective date | Day 0 | 30-day review clock begins; anniversary anchor set |
| First annual report | Within 60 days of the 1-year anniversary | Progress, enrollment, adverse events, plan |
| Subsequent annual reports | Within 60 days of each anniversary | Same content, cumulative safety picture |
| Safety reports | Promptly, per 21 CFR 312.32 | Serious and unexpected suspected adverse reactions |
| Protocol amendments | Before implementation | Changes to the investigation |
| Clinical hold response | Per FDA order | Corrective action if reporting lapses |
The 60-day window is the single most common scheduling trap. A sponsor-investigator who starts counting from first-patient-in rather than from IND effective date will file late almost every year.
Quantified context and the paperwork scale
The annual report is small relative to the clinical trial enterprise but large relative to a solo practice's bandwidth. A typical annual report for a single-site investigator-initiated trial runs roughly 10 to 30 pages depending on adverse event volume; the enrollment table alone requires age, race, and sex breakdowns that many site files do not maintain in that format.
The filing itself is inexpensive. There is no FDA fee for submitting an annual report. The cost is time: a realistic estimate for a physician with a modest site is 8 to 20 hours of compilation, review, and signature per cycle, concentrated in the 60-day window. Compare that to the IND itself, which carries a 30-day FDA review clock under 21 CFR 312.20, and to the safety reporting stream, which can generate dozens of individual reports per year at an active oncology or neurology site.
The scale question is why the sponsor-investigator model is usually reserved for small trials. A single investigator running a 15-patient pilot can absorb the annual report workload. A 200-patient program with a dozen sites generally needs a commercial or academic sponsor infrastructure.
Edge cases that change the analysis
The clean answer assumes one sponsor, one IND, one anniversary. Real practice is messier.
A common edge case is the transfer of sponsor obligations. If an investigator hands the IND to a company mid-study, the annual report duty moves with the sponsorship. The new sponsor must file going forward, but the transition year can produce duplicate or missed filings if the handoff is not documented.
Another edge is the inactive or on-hold IND. An IND on clinical hold is still an active IND for annual reporting purposes in most cases, and the annual report should address the hold status. A sponsor-investigator who stops enrolling but does not withdraw the IND still owes the report.
A third edge is the multi-site investigator-initiated trial. If one physician holds the IND and other sites enroll under it, the sponsor-investigator remains the filer, and the annual report must aggregate across sites. Site-level data collection gaps become the sponsor's reporting problem.
A fourth edge is combination with other reporting streams. An annual report is not a substitute for a safety report, a protocol amendment, or an annual progress report to an institutional review board. The IRB continuing review is a separate obligation, typically annual but on the IRB's schedule, not the IND anniversary.
Red flag: computing the due date from first enrollment instead of IND effective date. Red flag: filing a progress narrative without the required enrollment demographics table. Red flag: treating the annual report as a substitute for prompt serious adverse event reporting. Red flag: letting an IND go dormant without either filing the annual report or formally withdrawing the IND. Red flag: assuming a commercial sponsor's filing covers an investigator-held IND.
Misconceptions worth correcting
The most durable misconception is that the annual report is optional for small studies. It is not. The regulation does not scale by enrollment. A five-patient study owes the same annual report content as a five-hundred-patient study, though the report will be shorter.
A second misconception is that the report is a safety report. Safety reporting runs on a different, faster clock under 21 CFR 312.32. The annual report summarizes the year; it does not replace the prompt reporting of individual serious events.
A third misconception is that the IRB's continuing review satisfies the FDA obligation. They are separate regulators with separate schedules. An IRB approval letter is not an FDA filing.
A fourth misconception concerns who signs. The sponsor-investigator is the responsible party, but the report is a submission that carries regulatory weight. Delegating the drafting is common; delegating the accountability is not possible.
Practical actions for the sponsor-investigator
The sequence below is a general operational checklist for maintaining the annual report obligation. It is not protocol-specific advice.
First, document the IND effective date in the study file and set a recurring calendar reminder for 60 days before each anniversary. Second, maintain an enrollment log with age, race, and sex fields from day one, because retrofitting those categories at filing time is the most common cause of delay. Third, keep a running adverse event log separate from the safety reporting file, sized to the annual report's narrative requirements. Fourth, review the general investigational plan each cycle and write the year-ahead section before the deadline window opens, not during it. Fifth, confirm the IND is still active; if the study has ended, either file the final annual report or formally withdraw the IND.
A useful threshold: if the annual report is not drafted 30 days before its due date, escalate. The 60-day window exists to absorb review, not drafting.
Limits of this explanation and regulatory caution
This article describes the general framework of 21 CFR 312.33 and the sponsor-investigator role. It does not address state law, institutional policy, or the specific requirements of a particular review division, all of which can add obligations. The regulation is stable, but FDA guidance and individual protocol commitments can layer additional reporting requirements. When in doubt, the IND's own regulatory file and the assigned review division are the controlling sources.
This article is general educational information about FDA investigational drug reporting rules. It is not a legal opinion, regulatory determination, or treatment plan, and it does not promise any outcome. A sponsor-investigator should consult qualified regulatory counsel or the FDA review division for decisions about a specific IND.